The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease

Neurobiology of Aging

Volumn 36, Issue 3, 2015, Pages 1605.e13-1605.e20

  Louwersheimer, Eva ^a   Ramirez, Alfredo ^b   Cruchaga, Carlos ^c   Becker, Tim ^b,d   Kornhuber, Johannes ^e   Peters, Oliver ^f   Heilmann, Stefanie ^b   Wiltfang, Jens ^g   Jessen, Frank ^b,d   Visser, Pieter Jelle ^a,h   Scheltens, Philip ^a   Pijnenburg, Yolande A L ^a   Teunissen, Charlotte E ⁱ   Barkhof, Frederik ⁱ   van Swieten, John C ^i,j   Holstege, Henne ^a,i   Van der Flier, Wiesje M ^a,i  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF BONN   (Germany)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^e UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^h MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

ⁱ VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^j ERASMUS MEDICAL CENTER   (Netherlands)

more..

Author keywords

Alzheimer's disease; Endophenotypes; SNPs; SORL1

Indexed keywords

AMYLOID BETA PROTEIN; NEUROPEPTIDE RECEPTOR; SORTILIN RELATED RECEPTOR 1; TAU PROTEIN; THREONINE; UNCLASSIFIED DRUG; AMIDE; BIOLOGICAL MARKER; CARRIER PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; PHOSPHORAMIDIC ACID; PHOSPHORIC ACID; SORL1 PROTEIN, HUMAN;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CEREBROSPINAL FLUID ANALYSIS; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; ENDOPHENOTYPE; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HAPLOTYPE; HIPPOCAMPAL ATROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL TEST; MINI MENTAL STATE EXAMINATION; NEUROPATHOLOGY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN PHOSPHORYLATION; SINGLE NUCLEOTIDE POLYMORPHISM; SORL1 GENE; ALLELE; CEREBROSPINAL FLUID; GENETIC PREDISPOSITION; GENETICS; HIPPOCAMPUS; MIDDLE AGED; PATHOLOGY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; AMIDES; AMYLOID BETA-PEPTIDES; BIOMARKERS; FEMALE; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HIPPOCAMPUS; HUMANS; LDL-RECEPTOR RELATED PROTEINS; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; PHOSPHORIC ACIDS; POLYMORPHISM, SINGLE NUCLEOTIDE; TAU PROTEINS;

EID: 84923631414     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2014.12.007     Document Type: Article

References (61)

1. Abecasis G.R., Auton A., Brooks L.D., DePristo M.A., Durbin R.M., Handsaker R.E., Kang H.M., Marth G.T., McVean G.A. An integrated map of genetic variation from 1,092 human genomes. Nature 2012, 491:56-65.
2. Alexopoulos P., Guo L.H., Kratzer M., Westerteicher C., Kurz A., Perneczky R. Impact of SORL1 single nucleotide polymorphisms on Alzheimer's disease cerebrospinal fluid markers. Dement. Geriatr. Cogn. Disord 2011, 32:164-170.
3. Beecham G.W., Martin E.R., Li Y.J., Slifer M.A., Gilbert J.R., Haines J.L., Pericak-Vance M.A. Genome-wide association study implicates a chromosome 12 risk locus for late-onset Alzheimer disease. Am. J. Hum. Genet 2009, 84:35-43.
4. Caglayan S., Bauerfeind A., Schmidt V., Carlo A.S., Prabakaran T., Hubner N., Willnow T.E. Identification of Alzheimer disease risk genotype that predicts efficiency of SORL1 expression in the brain. Arch. Neurol 2012, 69:373-379.
5. Cruchaga C., Kauwe J.S., Harari O., Jin S.C., Cai Y., Karch C.M., Benitez B.A., Jeng A.T., Skorupa T., Carrell D., Bertelsen S., Bailey M., McKean D., Shulman J.M., De Jager P.L., Chibnik L., Bennett D.A., Arnold S.E., Harold D., Sims R., Gerrish A., Williams J., Van D., Lee V.M., Shaw L.M., Trojanowski J.Q., Haines J.L., Mayeux R., Pericak-Vance M.A., Farrer L.A., Schellenberg G.D., Peskind E.R., Galasko D., Fagan A.M., Holtzman D.M., Morris J.C., Goate A.M. GWAS of cerebrospinal fluid tau levels identifies risk variants for Alzheimer's disease. Neuron 2013, 78:256-268.
6. Cuenco T., Lunetta K.L., Baldwin C.T., McKee A.C., Guo J., Cupples L.A., Green R.C., St George-Hyslop P.H., Chui H., DeCarli C., Farrer L.A. Association of distinct variants in SORL1 with cerebrovascular and neurodegenerative changes related to Alzheimer disease. Arch. Neurol 2008, 65:1640-1648.
7. Derix M., Hofstede A., Teunisse A. CAMDEX-N: the Dutch version of the Cambridge Examination for Mental Disorders of the Elderly with automatic data processing. Gerontol. Geriatr 1991, 2:143-150.
8. Dodson S.E., Andersen O.M., Karmali V., Fritz J.J., Cheng D., Peng J., Levey A.I., Willnow T.E., Lah J.J. Loss of LR11/SORLA enhances early pathology in a mouse model of amyloidosis: evidence for a proximal role in Alzheimer's disease. J. Neurosci 2008, 28:12877-12886.
9. Dodson S.E., Gearing M., Lippa C.F., Montine T.J., Levey A.I., Lah J.J. LR11/SorLA expression is reduced in sporadic Alzheimer disease but not in familial Alzheimer disease. J. Neuropathol. Exp. Neurol 2006, 65:866-872.
10. Ewers M., Teipel S.J., Dietrich O., Schonberg S.O., Jessen F., Heun R., Scheltens P., van de P.L., Freymann N.R., Moeller H.J., Hampel H. Multicenter assessment of reliability of cranial MRI. Neurobiol. Aging 2006, 27:1051-1059.
11. Farrer L.A., Cupples L.A., Haines J.L., Hyman B., Kukull W.A., Mayeux R., Myers R.H., Pericak-Vance M.A., Risch N., van Duijn C.M. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA 1997, 278:1349-1356.
12. Fischl B. FreeSurfer. Neuroimage 2012, 62:774-781.
13. Folstein M.F., Folstein S.E., McHugh P.R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res 1975, 12:189-198.
14. Guo L.H., Westerteicher C., Wang X.H., Kratzer M., Tsolakidou A., Jiang M., Grimmer T., Laws S.M., Alexopoulos P., Bujo H., Kurz A., Perneczky R. SORL1 genetic variants and cerebrospinal fluid biomarkers of Alzheimer's disease. Eur. Arch. Psychiatry Clin. Neurosci 2012, 262:529-534.
15. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., Jones N., Thomas C., Stretton A., Morgan A.R., Lovestone S., Powell J., Proitsi P., Lupton M.K., Brayne C., Rubinsztein D.C., Gill M., Lawlor B., Lynch A., Morgan K., Brown K.S., Passmore P.A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A.D., Love S., Kehoe P.G., Hardy J., Mead S., Fox N., Rossor M., Collinge J., Maier W., Jessen F., Schurmann B., Heun R., van den B.H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frolich L., Hampel H., Hull M., Rujescu D., Goate A.M., Kauwe J.S., Cruchaga C., Nowotny P., Morris J.C., Mayo K., Sleegers K., Bettens K., Engelborghs S., De Deyn P.P., van B.C., Livingston G., Bass N.J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C.E., Tsolaki M., Singleton A.B., Guerreiro R., Muhleisen T.W., Nothen M.M., Moebus S., Jockel K.H., Klopp N., Wichmann H.E., Carrasquillo M.M., Pankratz V.S., Younkin S.G., Holmans P.A., O'Donovan M., Owen M.J., Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat. Genet 2013, 45:712.
16. Herold C., Steffens M., Brockschmidt F.F., Baur M.P., Becker T.I.N.T.E.R.S.N.P. genome-wide interaction analysis guided by a priori information. Bioinformatics 2009, 25:3275-3281.
17. Jack C.R., Bernstein M.A., Fox N.C., Thompson P., Alexander G., Harvey D., Borowski B., Britson P.J., Whitwell L., Ward C., Dale A.M., Felmlee J.P., Gunter J.L., Hill D.L., Killiany R., Schuff N., Fox-Bosetti S., Lin C., Studholme C., DeCarli C.S., Krueger G., Ward H.A., Metzger G.J., Scott K.T., Mallozzi R., Blezek D., Levy J., Debbins J.P., Fleisher A.S., Albert M., Green R., Bartzokis G., Glover G., Mugler J., Weiner M.W. The Alzheimer's Disease Neuroimaging Initiative (ADNI): MRI methods. J. Magn. Reson. Imaging 2008, 27:685-691.
18. Jack C.R., Knopman D.S., Jagust W.J., Petersen R.C., Weiner M.W., Aisen P.S., Shaw L.M., Vemuri P., Wiste H.J., Weigand S.D., Lesnick T.G., Pankratz V.S., Donohue M.C., Trojanowski J.Q. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013, 12:207-216.
19. Jacobsen L., Madsen P., Jacobsen C., Nielsen M.S., Gliemann J., Petersen C.M. Activation and functional characterization of the mosaic receptor SorLA/LR11. J. Biol. Chem 2001, 276:22788-22796.
20. Kauwe J.S., Cruchaga C., Bertelsen S., Mayo K., Latu W., Nowotny P., Hinrichs A.L., Fagan A.M., Holtzman D.M., Goate A.M. Validating predicted biological effects of Alzheimer's disease associated SNPs using CSF biomarker levels. J. Alzheimers Dis 2010, 21:833-842.
21. Kimura R., Yamamoto M., Morihara T., Akatsu H., Kudo T., Kamino K., Takeda M. SORL1 is genetically associated with Alzheimer disease in a Japanese population. Neurosci. Lett 2009, 461:177-180.
22. Kolsch H., Jessen F., Wiltfang J., Lewczuk P., Dichgans M., Kornhuber J., Frolich L., Heuser I., Peters O., Schulz J.B., Schwab S.G., Maier W. Influence of SORL1 gene variants: association with CSF amyloid-beta products in probable Alzheimer's disease. Neurosci. Lett 2008, 440:68-71.
23. Kornhuber J., Schmidtke K., Frolich L., Perneczky R., Wolf S., Hampel H., Jessen F., Heuser I., Peters O., Weih M., Jahn H., Luckhaus C., Hull M., Gertz H.J., Schroder J., Pantel J., Rienhoff O., Seuchter S.A., Ruther E., Henn F., Maier W., Wiltfang J. Early and differential diagnosis of dementia and mild cognitive impairment: design and cohort baseline characteristics of the German Dementia Competence Network. Dement. Geriatr. Cogn. Disord 2009, 27:404-417.
24. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., Letenneur L., Bettens K., Berr C., Pasquier F., Fievet N., Barberger-Gateau P., Engelborghs S., De D.P., Mateo I., Franck A., Helisalmi S., Porcellini E., Hanon O., de Pancorbo M.M., Lendon C., Dufouil C., Jaillard C., Leveillard T., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Bossu P., Piccardi P., Annoni G., Seripa D., Galimberti D., Hannequin D., Licastro F., Soininen H., Ritchie K., Blanche H., Dartigues J.F., Tzourio C., Gut I., van B.C., Alperovitch A., Lathrop M., Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat. Genet 2009, 41:1094-1099.
25. Lambert J.C., Ibrahim-Verbaas C.A., Harold D., Naj A.C., Sims R., Bellenguez C., DeStafano A.L., Bis J.C., Beecham G.W., Grenier-Boley B., Russo G., Thorton-Wells T.A., Jones N., Smith A.V., Chouraki V., Thomas C., Ikram M.A., Zelenika D., Vardarajan B.N., Kamatani Y., Lin C.F., Gerrish A., Schmidt H., Kunkle B., Dunstan M.L., Ruiz A., Bihoreau M.T., Choi S.H., Reitz C., Pasquier F., Cruchaga C., Craig D., Amin N., Berr C., Lopez O.L., De Jager P.L., Deramecourt V., Johnston J.A., Evans D., Lovestone S., Letenneur L., Moron F.J., Rubinsztein D.C., Eiriksdottir G., Sleegers K., Goate A.M., Fievet N., Huentelman M.W., Gill M., Brown K., Kamboh M.I., Keller L., Barberger-Gateau P., McGuiness B., Larson E.B., Green R., Myers A.J., Dufouil C., Todd S., Wallon D., Love S., Rogaeva E., Gallacher J., St George-Hyslop P., Clarimon J., Lleo A., Bayer A., Tsuang D.W., Yu L., Tsolaki M., Bossu P., Spalletta G., Proitsi P., Collinge J., Sorbi S., Sanchez-Garcia F., Fox N.C., Hardy J., iz Naranjo M.C., Bosco P., Clarke R., Brayne C., Galimberti D., Mancuso M., Matthews F., Moebus S., Mecocci P., Del Z.M., Maier W., Hampel H., Pilotto A., Bullido M., Panza F., Caffarra P., Nacmias B., Gilbert J.R., Mayhaus M., Lannefelt L., Hakonarson H., Pichler S., Carrasquillo M.M., Ingelsson M., Beekly D., Alvarez V., Zou F., Valladares O., Younkin S.G., Coto E., Hamilton-Nelson K.L., Gu W., Razquin C., Pastor P., Mateo I., Owen M.J., Faber K.M., Jonsson P.V., Combarros O., O'Donovan M.C., Cantwell L.B., Soininen H., Blacker D., Mead S., Mosley T.H., Bennett D.A., Harris T.B., Fratiglioni L., Holmes C., de Bruijn R.F., Passmore P., Montine T.J., Bettens K., Rotter J.I., Brice A., Morgan K., Foroud T.M., Kukull W.A., Hannequin D., Powell J.F., Nalls M.A., Ritchie K., Lunetta K.L., Kauwe J.S., Boerwinkle E., Riemenschneider M., Boada M., Hiltuenen M., Martin E.R., Schmidt R., Rujescu D., Wang L.S., Dartigues J.F., Mayeux R., Tzourio C., Hofman A., Nothen M.M., Graff C., Psaty B.M., Jones L., Haines J.L., Holmans P.A., Lathrop M., Pericak-Vance M.A., Launer L.J., Farrer L.A., van Duijn C.M., van B.C., Moskvina V., Seshadri S., Williams J., Schellenberg G.D., Amouyel P. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nat. Genet 2013, 45:1452-1458.
26. Laumet G., Chouraki V., Grenier-Boley B., Legry V., Heath S., Zelenika D., Fievet N., Hannequin D., Delepine M., Pasquier F., Hanon O., Brice A., Epelbaum J., Berr C., Dartigues J.F., Tzourio C., Campion D., Lathrop M., Bertram L., Amouyel P., Lambert J.C. Systematic analysis of candidate genes for Alzheimer's disease in a French, genome-wide association study. J. Alzheimers Dis 2010, 20:1181-1188.
27. Lee J.H., Cheng R., Honig L.S., Vonsattel J.P., Clark L., Mayeux R. Association between genetic variants in SORL1 and autopsy-confirmed Alzheimer disease. Neurology 2008, 70:887-889.
28. Li Y., Rowland C., Catanese J., Morris J., Lovestone S., O'Donovan M.C., Goate A., Owen M., Williams J., Grupe A. SORL1 variants and risk of late-onset Alzheimer's disease. Neurobiol. Dis 2008, 29:293-296.
29. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
30. McKhann G.M., Knopman D.S., Chertkow H., Hyman B.T., Jack C.R., Kawas C.H., Klunk W.E., Koroshetz W.J., Manly J.J., Mayeux R., Mohs R.C., Morris J.C., Rossor M.N., Scheltens P., Carrillo M.C., Thies B., Weintraub S., Phelps C.H. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011, 7:263-269.
31. Meng Y., Lee J.H., Cheng R. St George-Hyslop P, Mayeux R, Farrer LA. Association between SORL1 and Alzheimer's disease in a genome-wide study. Neuroreport 2007, 18:1761-1764.
32. Mulder C., Verwey N.A., van der Flier W.M., Bouwman F.H., Kok A., van Elk E.J., Scheltens P., Blankenstein M.A. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease. Clin. Chem 2010, 56:248-253.
33. Ning M., Yang Y., Zhang Z., Chen Z., Zhao T., Zhang D., Zhou D., Xu J., Liu Z., Wang Y., Liu Y., Zhao X., Li W., Li S., He L. Amyloid-beta-Related Genes SORL1 and ACE are Genetically Associated With Risk for Late-onset Alzheimer Disease in the Chinese Population. Alzheimer Dis. Assoc. Disord. 2010, 24:390-396.
34. Nixon R.A. Niemann-Pick Type C disease and Alzheimer's disease: the APP-endosome connection fattens up. Am. J. Pathol 2004, 164:757-761.
35. Ossenkoppele R., van der Flier W.M., Zwan M.D., Adriaanse S.F., Boellaard R., Windhorst A.D., Barkhof F., Lammertsma A.A., Scheltens P., van Berckel B.N. Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. Neurology 2013, 80:359-365.
36. Pievani M., Galluzzi S., Thompson P.M., Rasser P.E., Bonetti M., Frisoni G.B. APOE4 is associated with greater atrophy of the hippocampal formation in Alzheimer's disease. Neuroimage 2011, 55:909-919.
37. Popp J., Lewczuk P., Frommann I., Kolsch H., Kornhuber J., Maier W., Jessen F. Cerebrospinal fluid markers for Alzheimer's disease over the lifespan: effects of age and the APOEepsilon4 genotype. J. Alzheimers Dis 2010, 22:459-468.
38. Popp J., Meichsner S., Kolsch H., Lewczuk P., Maier W., Kornhuber J., Jessen F., Lutjohann D. Cerebral and extracerebral cholesterol metabolism and CSF markers of Alzheimer's disease. Biochem. Pharmacol 2013, 86:37-42.
39. Prince J.A., Zetterberg H., Andreasen N., Marcusson J., Blennow K. APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of Abeta42. Neurology 2004, 62:2116-2118.
40. Purcell S., Neale B., Todd-Brown K., Thomas L., Ferreira M.A., Bender D., Maller J., Sklar P., de Bakker P.I., Daly M.J., Sham P.C. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet 2007, 81:559-575.
41. Ramirez A., van der Flier W.M., Herold C., Ramonet D., Heilmann S., Lewczuk P., Popp J., Lacour A., Drichel D., Louwersheimer E., Kummer M.P., Cruchaga C., Hoffmann P., Teunissen C., Holstege H., Kornhuber J., Peters O., Naj A.C., Chouraki V., Bellenguez C., Gerrish A., Heun R., Frolich L., Hull M., Buscemi L., Herms S., Kolsch H., Scheltens P., Breteler M.M., Ruther E., Wiltfang J., Goate A., Jessen F., Maier W., Heneka M.T., Becker T., Nothen M.M. SUCLG2 identified as both a determinator of CSF Abeta1-42 levels and an attenuator of cognitive decline in Alzheimer's disease. Hum. Mol. Genet. 2014, 23:6644-6658.
42. Reitz C., Cheng R., Rogaeva E., Lee J.H., Tokuhiro S., Zou F., Bettens K., Sleegers K., Tan E.K., Kimura R., Shibata N., Arai H., Kamboh M.I., Prince J.A., Maier W., Riemenschneider M., Owen M., Harold D., Hollingworth P., Cellini E., Sorbi S., Nacmias B., Takeda M., Pericak-Vance M.A., Haines J.L., Younkin S., Williams J., van B.C., Farrer L.A., St George-Hyslop P.H., Mayeux R. Meta-analysis of the association between variants in SORL1 and Alzheimer disease. Arch. Neurol 2011, 68:99-106.
43. Reitz C., Mayeux R. Endophenotypes in normal brain morphology and Alzheimer's disease: a review. Neuroscience 2009, 164:174-190.
44. Reynolds C.A., Hong M.G., Eriksson U.K., Blennow K., Johansson B., Malmberg B., Berg S., Gatz M., Pedersen N.L., Bennet A.M., Prince J.A. Sequence variation in SORL1 and dementia risk in Swedes. Neurogenetics 2010, 11:139-142.
45. Rogaeva E., Meng Y., Lee J.H., Gu Y., Kawarai T., Zou F., Katayama T., Baldwin C.T., Cheng R., Hasegawa H., Chen F., Shibata N., Lunetta K.L., Pardossi-Piquard R., Bohm C., Wakutani Y., Cupples L.A., Cuenco K.T., Green R.C., Pinessi L., Rainero I., Sorbi S., Bruni A., Duara R., Friedland R.P., Inzelberg R., Hampe W., Bujo H., Song Y.Q., Andersen O.M., Willnow T.E., Graff-Radford N., Petersen R.C., Dickson D., Der S.D., Fraser P.E., Schmitt-Ulms G., Younkin S., Mayeux R., Farrer L.A., St George-Hyslop P. The neuronal sortilin-related receptor SORL1 is genetically associated with Alzheimer disease. Nat. Genet 2007, 39:168-177.
46. Rosen W.G., Mohs R.C., Davis K.L. A new rating scale for Alzheimer's disease. Am. J. Psychiatry 1984, 141:1356-1364.
47. Saykin A.J., Shen L., Foroud T.M., Potkin S.G., Swaminathan S., Kim S., Risacher S.L., Nho K., Huentelman M.J., Craig D.W., Thompson P.M., Stein J.L., Moore J.H., Farrer L.A., Green R.C., Bertram L., Jack C.R., Weiner M.W. Alzheimer's Disease Neuroimaging Initiative biomarkers as quantitative phenotypes: Genetics core aims, progress, and plans. Alzheimers Dement 2010, 6:265-273.
48. Scheltens P., Launer L.J., Barkhof F., Weinstein H.C., van Gool W.A. Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: interobserver reliability. J Neurol 1995, 242:557-560.
49. Scriver C. Allelic and locus heterogeneity. Encyclopedia of life sciences 2005, 10.1038/npg.els.0005481.
50. Seshadri S., Fitzpatrick A.L., Ikram M.A., DeStefano A.L., Gudnason V., Boada M., Bis J.C., Smith A.V., Carassquillo M.M., Lambert J.C., Harold D., Schrijvers E.M., Ramirez-Lorca R., Debette S., Longstreth W.T., Janssens A.C., Pankratz V.S., Dartigues J.F., Hollingworth P., Aspelund T., Hernandez I., Beiser A., Kuller L.H., Koudstaal P.J., Dickson D.W., Tzourio C., Abraham R., Antunez C., Du Y., Rotter J.I., Aulchenko Y.S., Harris T.B., Petersen R.C., Berr C., Owen M.J., Lopez-Arrieta J., Varadarajan B.N., Becker J.T., Rivadeneira F., Nalls M.A., Graff-Radford N.R., Campion D., Auerbach S., Rice K., Hofman A., Jonsson P.V., Schmidt H., Lathrop M., Mosley T.H., Au R., Psaty B.M., Uitterlinden A.G., Farrer L.A., Lumley T., Ruiz A., Williams J., Amouyel P., Younkin S.G., Wolf P.A., Launer L.J., Lopez O.L., van Duijn C.M., Breteler M.M. Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA 2010, 303:1832-1840.
51. Shaw L.M., Vanderstichele H., Knapik-Czajka M., Clark C.M., Aisen P.S., Petersen R.C., Blennow K., Soares H., Simon A., Lewczuk P., Dean R., Siemers E., Potter W., Lee V.M., Trojanowski J.Q. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009, 65:403-413.
52. Shen L., Kim S., Risacher S.L., Nho K., Swaminathan S., West J.D., Foroud T., Pankratz N., Moore J.H., Sloan C.D., Huentelman M.J., Craig D.W., Dechairo B.M., Potkin S.G., Jack C.R., Weiner M.W., Saykin A.J. Whole genome association study of brain-wide imaging phenotypes for identifying quantitative trait loci in MCI and AD: A study of the ADNI cohort. Neuroimage 2010, 53:1051-1063.
53. Sluimer J.D., Vrenken H., Blankenstein M.A., Fox N.C., Scheltens P., Barkhof F., van der Flier W.M. Whole-brain atrophy rate in Alzheimer disease: identifying fast progressors. Neurology 2008, 70:1836-1841.
54. Storey J.D., Tibshirani R. Statistical significance for genomewide studies. Proc. Natl. Acad. Sci. U. S. A 2003, 100:9440-9445.
55. Tan E.K., Lee J., Chen C.P., Teo Y.Y., Zhao Y., Lee W.L. SORL1 haplotypes modulate risk of Alzheimer's disease in Chinese. Neurobiol Aging 2009, 30:1048-1051.
56. Teipel S.J., Pruessner J.C., Faltraco F., Born C., Rocha-Unold M., Evans A., Moller H.J., Hampel H. Comprehensive dissection of the medial temporal lobe in AD: measurement of hippocampus, amygdala, entorhinal, perirhinal and parahippocampal cortices using MRI. J. Neurol 2006, 253:794-800.
57. van der Flier W.M., Pijnenburg Y.A., Fox N.C., Scheltens P. Early-onset versus late-onset Alzheimer's disease: the case of the missing APOE varepsilon4 allele. Lancet Neurol 2011, 10:280-288.
58. van der Flier W.M., Pijnenburg Y.A., Prins N., Lemstra A.W., Bouwman F.H., Teunissen C.E., van Berckel B.N., Stam C.J., Barkhof F., Visser P.J., van E.E., Scheltens P. Optimizing Patient Care. Research: The Amsterdam Dementia Cohort. J. Alzheimers Dis. 2014, 41:313-327.
59. van der Flier W.M., Schoonenboom S.N., Pijnenburg Y.A., Fox N.C., Scheltens P. The effect of APOE genotype on clinical phenotype in Alzheimer disease. Neurology 2006, 67:526-527.
60. van der Vlies A.E., Koedam E.L., Pijnenburg Y.A., Twisk J.W., Scheltens P., van der Flier W.M. Most rapid cognitive decline in APOE epsilon4 negative Alzheimer's disease with early onset. Psychol Med 2009, 39:1907-1911.
61. van Vliet P. Cholesterol and late-life cognitive decline. J. Alzheimers Dis 2012, 2(30 Suppl):S147-S162.